Survival adjusting for crossover: Phase 3 study of ibrutinib vs. chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma

Steven Coutre; Alessandra Tedeschi; Tadeusz Robak; Paul M. Barr; Carolyn Owen; Osnat Bairey; Jan Burger; Cathy Zhou; Lori Styles; Danelle F. James; Thomas J. Kipps

doi:10.3324/haematol.2017.175380

Survival adjusting for crossover: Phase 3 study of ibrutinib vs. chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma

Steven Coutre^*, Alessandra Tedeschi, Tadeusz Robak, Paul M. Barr, Carolyn Owen, Osnat Bairey, Jan Burger, Cathy Zhou, Lori Styles, Danelle F. James, Thomas J. Kipps

^*Corresponding author for this work

Hematology

Research output: Contribution to journal › Letter › peer-review

5 Scopus citations

Original language	English
Pages (from-to)	e249-e251
Journal	Haematologica
Volume	103
Issue number	6
DOIs	https://doi.org/10.3324/haematol.2017.175380
State	Published - 3 Jun 2018

Funding

Funders	Funder number
National Cancer Institute	P30CA016672
AbbVie
Pharmacyclics

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3324/haematol.2017.175380

Cite this

Coutre, S., Tedeschi, A., Robak, T., Barr, P. M., Owen, C., Bairey, O., Burger, J., Zhou, C., Styles, L., James, D. F., & Kipps, T. J. (2018). Survival adjusting for crossover: Phase 3 study of ibrutinib vs. chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica, 103(6), e249-e251. https://doi.org/10.3324/haematol.2017.175380

@article{76491c168b0d4fbe8d4e5004d5142551,

title = "Survival adjusting for crossover: Phase 3 study of ibrutinib vs. chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma",

author = "Steven Coutre and Alessandra Tedeschi and Tadeusz Robak and Barr, {Paul M.} and Carolyn Owen and Osnat Bairey and Jan Burger and Cathy Zhou and Lori Styles and James, {Danelle F.} and Kipps, {Thomas J.}",

note = "Funding Information: 1Stanford University School of Medicine, CA, USA;2ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy;3Medical University of Lodz, Poland;4Wilmot Cancer Institute, University of Rochester Cancer Center, NY, USA;5Tom Baker Cancer Centre, University of Calgary, Canada;6Rabin Medical Center, Beilinson Campus, Petah Tikvah, Israel;7Sackler Faculty of Medicine, University, Tel Aviv, Israel;8University of Texas MD Anderson Cancer Center, Houston, TX, USA;8Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA and 10University of California, San Diego, Moores Cancer Center, La Jolla, CA, USA Correspondence: [email protected] doi:10.3324/haematol.2017.175380 Acknowledgments: the authors would like to thank the patients who participated in the study, their supporters, and the investigators and clinical research staff from the study centers. This manuscript was developed with editorial support from Stacey Rose, PhD, and funded by Pharmacyclics LLC, an AbbVie Company.",

year = "2018",

month = jun,

day = "3",

doi = "10.3324/haematol.2017.175380",

language = "אנגלית",

volume = "103",

pages = "e249--e251",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "6",

}

Coutre, S, Tedeschi, A, Robak, T, Barr, PM, Owen, C, Bairey, O, Burger, J, Zhou, C, Styles, L, James, DF & Kipps, TJ 2018, 'Survival adjusting for crossover: Phase 3 study of ibrutinib vs. chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma', Haematologica, vol. 103, no. 6, pp. e249-e251. https://doi.org/10.3324/haematol.2017.175380

TY - JOUR

T1 - Survival adjusting for crossover

T2 - Phase 3 study of ibrutinib vs. chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma

AU - Coutre, Steven

AU - Tedeschi, Alessandra

AU - Robak, Tadeusz

AU - Barr, Paul M.

AU - Owen, Carolyn

AU - Bairey, Osnat

AU - Burger, Jan

AU - Zhou, Cathy

AU - Styles, Lori

AU - James, Danelle F.

AU - Kipps, Thomas J.

N1 - Funding Information: 1Stanford University School of Medicine, CA, USA;2ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy;3Medical University of Lodz, Poland;4Wilmot Cancer Institute, University of Rochester Cancer Center, NY, USA;5Tom Baker Cancer Centre, University of Calgary, Canada;6Rabin Medical Center, Beilinson Campus, Petah Tikvah, Israel;7Sackler Faculty of Medicine, University, Tel Aviv, Israel;8University of Texas MD Anderson Cancer Center, Houston, TX, USA;8Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA and 10University of California, San Diego, Moores Cancer Center, La Jolla, CA, USA Correspondence: [email protected] doi:10.3324/haematol.2017.175380 Acknowledgments: the authors would like to thank the patients who participated in the study, their supporters, and the investigators and clinical research staff from the study centers. This manuscript was developed with editorial support from Stacey Rose, PhD, and funded by Pharmacyclics LLC, an AbbVie Company.

PY - 2018/6/3

Y1 - 2018/6/3

UR - http://www.scopus.com/inward/record.url?scp=85048052554&partnerID=8YFLogxK

U2 - 10.3324/haematol.2017.175380

DO - 10.3324/haematol.2017.175380

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???

C2 - 29170253

AN - SCOPUS:85048052554

SN - 0390-6078

VL - 103

SP - e249-e251

JO - Haematologica

JF - Haematologica

IS - 6

ER -

Survival adjusting for crossover: Phase 3 study of ibrutinib vs. chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma

Funding

UN SDGs

Access to Document

Other files and links

Cite this